Unlocking the Potential of Site-Directed Therapies .
The discovery of oxMIF created a unique opportunity for disease-selective targeting. Generated specifically at sites of inflammation and cancer, oxMIF enables therapeutic activity to be focused on diseased tissues. ImmunoOne's oxMIF platform and associated assets provide partners with a differentiated foundation for developing novel therapeutics and diagnostics.
ON104 - Chronic Inflammation
ON104 is a fully human, next-generation monoclonal antibody designed to neutralize oxMIF with precision. Its silenced effector functions eliminate unwanted immune cell activation, while its optimized biophysical and pharmacokinetic profile makes it well suited for the treatment of rheumatoid arthritis, nephritis, and related inflammatory conditions.
ON104 - Chronic Inflammation
ON104 is a fully human, next-generation monoclonal antibody designed to neutralize oxMIF with precision. Its silenced effector functions eliminate unwanted immune cell activation, while its optimized biophysical and pharmacokinetic profile makes it well suited for the treatment of rheumatoid arthritis, nephritis, and related inflammatory conditions.
ON104 neutralizes the broad, disease-driving activities of oxMIF. Because oxMIF can override the immunosuppressive effects of glucocorticoids, ON104 works in concert with existing immunosuppressant therapies enhancing their effectiveness at the site of disease.
ON104 neutralizes the broad, disease-driving activities of oxMIF. Because oxMIF can override the immunosuppressive effects of glucocorticoids, ON104 works in concert with existing immunosuppressant therapies enhancing their effectiveness at the site of disease.
ON203 - Solid Tumors
ON203 is a fully human, next-generation monoclonal antibody designed to neutralize oxMIF and activate the innate immune response in solid tumors, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Its optimized tumor penetration and pharmacokinetic profile make it well suited for the treatment of colorectal, lung, and other solid tumor indications
ON203 - Solid Tumors
ON203 is a fully human, next-generation monoclonal antibody designed to neutralize oxMIF and activate the innate immune response in solid tumors, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Its optimized tumor penetration and pharmacokinetic profile make it well suited for the treatment of colorectal, lung, and other solid tumor indications
By inhibiting oxMIF-driven pro-tumorigenic activity and engaging cytotoxic immune mechanisms, ON203 delivers meaningful therapeutic impact — as a monotherapy or in combination with standard-of-care regimens.
By inhibiting oxMIF-driven pro-tumorigenic activity and engaging cytotoxic immune mechanisms, ON203 delivers meaningful therapeutic impact — as a monotherapy or in combination with standard-of-care regimens.
oxMIF: We Discovered It. We Named It. We Are Drugging It.
LICENSING
ImmunoOne's oxMIF platform and associated assets offer partners a unique opportunity to develop innovative therapeutic and diagnostic solutions.
Immunology: ON104
Therapeutic mAb - Rheumatoid Arthritis and Nephritis
Oncology: ON203
Therapeutic mAb - Colorectal, Lung Cancer